InvestSMART

Paradigm Biopharmaceuticals Limited (ASX:PAR)

ALERT: Price-sensitive ASX Announcement for PAR
Current share price for PAR : $0.175 0.01 (6.06%)+
Announcement
Release
22 Jul 2026 8:18AM
Price at Release
$0.165
Full Release
download
Summary
Paradigm Biopharmaceuticals Limited has bolstered its financial position by securing a total of $5.75 million from the Australian Government's R&D Tax Incentive and an amended income tax assessment. This sum includes a $4.82 million refund for the 2025 financial year and an additional $0.93 million for the 2023 financial year. The funds will support the company's ongoing Phase 3 clinical program focused on injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis, as well as regulatory, manufacturing, and partnering activities. The Australian R&D Tax Incentive is aimed at fostering innovation by providing tax offsets for eligible R&D activities.
Key Points
  • Paradigm Biopharmaceuticals received a $4.82 million R&D Tax Incentive refund for FY25 and $0.93 million from an amended FY23 income tax assessment.
  • Total cash receipts of $5.75 million will support Paradigm's Phase 3 osteoarthritis clinical program.
  • Funds enhance financial stability and assist in regulatory, manufacturing, and global partnering initiatives.
  • The R&D Tax Incentive program provides refundable tax offsets for qualifying Australian R&D expenditure.
  • Paradigm focuses on developing injectable pentosan polysulfate sodium (iPPS) for treating knee osteoarthritis.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.